Angewandte Chemie, Год журнала: 2024, Номер unknown
Опубликована: Сен. 18, 2024
Abstract Ventricular arrhythmias (VAs) triggered by myocardial infarction (MI) are the leading cause of sudden cardiac mortality worldwide. Current therapeutic strategies for managing MI‐induced VAs, such as left stellate ganglion resection and ablation, suboptimal, highlighting need to explore safer more effective intervention strategies. Herein, we rationally designed two supramolecular sonosensitizers RuA RuB , engineered through acceptor modification generate moderate reactive oxygen species (ROS) modulate VAs. Both demonstrated high ultrasound (US)‐activated ROS production efficiency, with singlet ( 1 O 2 ) quantum yield (Φ Δ 0.70 0.88, respectively, surpassing ligand IR1105 conventional sonosensitizer ICG =0.40). In vitro, at a modest concentration under US intensity notably boosts pro‐survival autophagy in microglia BV2 cell. To improve vivo stability biocompatibility, was further encapsulated into DSPE‐PEG 5000 prepare nanoparticles NPs). studies after microinjection NPs paraventricular nucleus (PVN) subsequent exposure, that NPs‐mediated modulation effectively suppresses sympathetic nervous activity (SNA) inflammatory responses, thereby preventing Importantly, no tissue injury observed post modulation. This work pioneers design long‐wave emission sonosensitizers, offering new insights regulating cardiovascular diseases.
Язык: Английский